日本富士 流感病毒檢測(cè)試劑盒

廣州健侖生物科技有限公司

廣州健侖長(zhǎng)期供應(yīng)各種流感檢測(cè)試劑，包括進(jìn)口和國產(chǎn)的品牌，主要包括日本富士瑞必歐、日本生研、美國BD、美國NovaBios、美國binaxNOW、英國clearview、廣州創(chuàng)侖等主流品牌。

主要檢測(cè)：甲型流感病毒檢測(cè)試劑、乙型流感病毒檢測(cè)試劑、甲乙型流感病毒檢測(cè)試劑、A+B流感病毒檢測(cè)試劑盒、流感病毒抗原快速檢測(cè)卡、流感病毒抗體快速檢測(cè)試劑盒、流感快速檢測(cè)試劑 c1c2。

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、化妝品檢測(cè)、食品安全檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

歡迎咨詢

歡迎咨詢2042552662

日本富士 

【產(chǎn)品說明書】

【原理】 

流感病毒檢測(cè)卡以雙抗體夾心法為基礎(chǔ)，采用免疫層析金標(biāo)記技術(shù)，快速檢測(cè)流感病毒。  

【試劑組成】 

1. 流感病毒快速檢測(cè)卡40片/盒    

2. 樣本稀釋液40管/盒      

3. 棉簽40支/盒  

【操作方法】 一、樣品制備： 

1. 本檢測(cè)卡采集樣品為眼、氣管分泌物。將棉簽插入分泌物zui多的部位，輕輕搖動(dòng)棉簽，讓棉簽充分吸收分泌物。 

2. 將棉簽在稀釋液中充分?jǐn)嚢璨⒎磸?fù)擠壓試管壁，讓分泌物充分溶解到稀釋液中，得到待檢樣品。 

3. 樣品一般須當(dāng)即進(jìn)行檢測(cè)，否則應(yīng)冷藏保存，超過24小時(shí)的，應(yīng)該冷凍保存。  

二、操作步驟： 

1. 使用前將試劑盒和樣品恢復(fù)至室溫。 

2. 將棉簽浸入裝有樣品稀釋液的試管，充分?jǐn)嚢杌靹蚝螅靡淮涡缘喂苋∩锨逡骸?/span>

3. 取出檢測(cè)卡，開封后平放于桌面上，從滴管中緩慢而準(zhǔn)確地逐滴加入2–3滴混合液。 

4. 加樣品液后，約30秒內(nèi)，紅色的液體從靠樣品孔的觀察窗邊緣涌出。朝另一方向流動(dòng)。 

5. 五分鐘后判斷結(jié)果，超過三十分鐘的結(jié)果判讀無效。  

【結(jié)果判定】        

1. 陽性：在觀察孔內(nèi)，若對(duì)照線顯色，檢測(cè)線同時(shí)顯色，判為陽性(如圖一、圖二)。陽性結(jié)果表明檢測(cè)液

中含有流感病毒。 

2. 陰性：在觀察孔內(nèi)，若對(duì)照線顯色，而檢測(cè)線不顯色，判為陰性（如圖三）。陰性結(jié)果表明檢測(cè)液中不含流感病毒。 

3. 無效：在觀察孔內(nèi)，若對(duì)照線不顯色，則結(jié)果無效，建議重新測(cè)試(如圖四、圖五)。   

【注意事項(xiàng)】 

1. 本品如果購買時(shí)發(fā)現(xiàn)過期、破損、污染、無效的產(chǎn)品，請(qǐng)?jiān)谫徺I處進(jìn)行更換。  

2. 測(cè)試樣品來自動(dòng)物，可能有潛在感染性，樣品和使用過的試劑應(yīng)被看作微生物危險(xiǎn)品處理。

3. 所有檢測(cè)卡啟封后馬上使用，此前不要隨意打開。 

4. 本品為一次性產(chǎn)品，請(qǐng)勿二次使用；請(qǐng)勿使用非本品隨附的稀釋液。  

【儲(chǔ)存及有效期】 

1. 保存于干燥陰涼處（2~30℃），有效期為18個(gè)月，生產(chǎn)日期見外包裝盒。

2. 打開包裝后，在1小時(shí)內(nèi)使用。

【產(chǎn)品介紹】

日本富士 

發(fā)展
得益于新醫(yī)改穩(wěn)步推進(jìn)的帶動(dòng)作用，醫(yī)藥制造業(yè)工業(yè)增加值總體保持平穩(wěn)增長(zhǎng)趨勢(shì)。2012年上半年，在國內(nèi)經(jīng)濟(jì)持續(xù)下行的背景下，醫(yī)藥制造業(yè)工業(yè)增加值增速逐步下行。進(jìn)入3季度以來，在“毒膠囊”效應(yīng)趨緩和政府相繼出臺(tái)《“十二五”期間衛(wèi)生扶貧工作指導(dǎo)意見》、《關(guān)于開展城鄉(xiāng)居民大病保險(xiǎn)工作的指導(dǎo)意見》等一系列利好政策的帶動(dòng)下，醫(yī)藥行業(yè)市場(chǎng)景氣開始回升，醫(yī)藥制造業(yè)產(chǎn)銷增速扭轉(zhuǎn)了上半年以來持續(xù)下滑趨勢(shì)，工業(yè)增加值增速明顯趨穩(wěn)、產(chǎn)品銷售收入增速開始回升。其中，前三季度，醫(yī)藥制造業(yè)工業(yè)增加值增速為14.6%，比上半年回升0.3個(gè)百分點(diǎn)；醫(yī)藥制造業(yè)實(shí)現(xiàn)產(chǎn)品銷售收入12069.91億元，同比增長(zhǎng)19.52%，比上半年提高0.45個(gè)百分點(diǎn)。
前三季度，我國累計(jì)醫(yī)藥品出口額89.58億美元，同比僅增長(zhǎng)1.8%，增速比上年同期下降8.4個(gè)百分點(diǎn)，比上半年下降1.5百分點(diǎn)。值得注意的是，盡管醫(yī)藥品單月進(jìn)口額震蕩下滑，但醫(yī)藥品進(jìn)口額整體仍保持較高水平。前三季度，我國醫(yī)藥品累計(jì)進(jìn)口額102.31億美元，同比增長(zhǎng)23%，增速比上年同期下滑18.7個(gè)百分點(diǎn)，比上半年下降6.9個(gè)百分點(diǎn)。其中，單月進(jìn)口額從7月的12.01億美元震蕩下行至9月的11.23億美元。
展望2013年，一方面，藥品招標(biāo)逐步趨于良性。“基藥招標(biāo)”的“*中標(biāo)”模式逐步改善，政府通過“基本藥物試行國家統(tǒng)一定價(jià)”可以有效地防止或規(guī)避低價(jià)惡性競(jìng)爭(zhēng)和各省的比價(jià)效應(yīng)，有利于提高藥企的盈利能力。同時(shí)，即將出臺(tái)的新版基藥目錄的擴(kuò)容將帶動(dòng)基層市場(chǎng)的持續(xù)增長(zhǎng)，主要是由于基本藥物報(bào)銷比例明顯高于非基本藥物，基藥品種的增加無疑將會(huì)加大政府醫(yī)藥衛(wèi)生投入比例。因此，預(yù)計(jì)2013年醫(yī)藥制造業(yè)利潤增速將繼續(xù)回升。
從長(zhǎng)遠(yuǎn)來看，國家工信部發(fā)布的《醫(yī)藥工業(yè)“十二五”發(fā)展規(guī)劃》明確提出發(fā)展目標(biāo)為形成5個(gè)以上年銷售收入達(dá)到500億元企業(yè)，100個(gè)100億元企業(yè)，*位企業(yè)銷售收入占行業(yè)50%的目標(biāo)。在上述政策鼓勵(lì)及行業(yè)競(jìng)爭(zhēng)背景下，未來行業(yè)集中度將進(jìn)一步提高，凸顯企業(yè)規(guī)模的重要性，企業(yè)核心競(jìng)爭(zhēng)力的打造將決定企業(yè)未來的發(fā)展。
2012年，三年新醫(yī)改結(jié)束，醫(yī)藥行業(yè)進(jìn)入后醫(yī)改時(shí)代。回首三年新醫(yī)改，政府不斷加大對(duì)醫(yī)療領(lǐng)域的投入，中國醫(yī)藥市場(chǎng)整體擴(kuò)容，中國醫(yī)藥產(chǎn)業(yè)經(jīng)歷*的發(fā)展機(jī)遇。
醫(yī)藥產(chǎn)業(yè)是國民經(jīng)濟(jì)的重要組成部分，與人民群眾的生命健康和生活質(zhì)量等切身利益密切相關(guān)，是全社會(huì)關(guān)注的熱點(diǎn)，同時(shí)也是構(gòu)建社會(huì)主義和諧社會(huì)的重要內(nèi)容。改革開放以來，中國醫(yī)藥行業(yè)一直保持較快的增長(zhǎng)速度，1978-2011年，醫(yī)藥工業(yè)規(guī)模年均遞增均處于15%以上，規(guī)模不斷擴(kuò)大，經(jīng)濟(jì)運(yùn)行質(zhì)量與效益不斷提高。發(fā)展
得益于新醫(yī)改穩(wěn)步推進(jìn)的帶動(dòng)作用，醫(yī)藥制造業(yè)工業(yè)增加值總體保持平穩(wěn)增長(zhǎng)趨勢(shì)。2012年上半年，在國內(nèi)經(jīng)濟(jì)持續(xù)下行的背景下，醫(yī)藥制造業(yè)工業(yè)增加值增速逐步下行。進(jìn)入3季度以來，在“毒膠囊”效應(yīng)趨緩和政府相繼出臺(tái)《“十二五”期間衛(wèi)生扶貧工作指導(dǎo)意見》、《關(guān)于開展城鄉(xiāng)居民大病保險(xiǎn)工作的指導(dǎo)意見》等一系列利好政策的帶動(dòng)下，醫(yī)藥行業(yè)市場(chǎng)景氣開始回升，醫(yī)藥制造業(yè)產(chǎn)銷增速扭轉(zhuǎn)了上半年以來持續(xù)下滑趨勢(shì)，工業(yè)增加值增速明顯趨穩(wěn)、產(chǎn)品銷售收入增速開始回升。其中，前三季度，醫(yī)藥制造業(yè)工業(yè)增加值增速為14.6%，比上半年回升0.3個(gè)百分點(diǎn)；醫(yī)藥制造業(yè)實(shí)現(xiàn)產(chǎn)品銷售收入12069.91億元，同比增長(zhǎng)19.52%，比上半年提高0.45個(gè)百分點(diǎn)。
前三季度，我國累計(jì)醫(yī)藥品出口額89.58億美元，同比僅增長(zhǎng)1.8%，增速比上年同期下降8.4個(gè)百分點(diǎn)，比上半年下降1.5百分點(diǎn)。值得注意的是，盡管醫(yī)藥品單月進(jìn)口額震蕩下滑，但醫(yī)藥品進(jìn)口額整體仍保持較高水平。前三季度，我國醫(yī)藥品累計(jì)進(jìn)口額102.31億美元，同比增長(zhǎng)23%，增速比上年同期下滑18.7個(gè)百分點(diǎn)，比上半年下降6.9個(gè)百分點(diǎn)。其中，單月進(jìn)口額從7月的12.01億美元震蕩下行至9月的11.23億美元。
展望2013年，一方面，藥品招標(biāo)逐步趨于良性。“基藥招標(biāo)”的“*中標(biāo)”模式逐步改善，政府通過“基本藥物試行國家統(tǒng)一定價(jià)”可以有效地防止或規(guī)避低價(jià)惡性競(jìng)爭(zhēng)和各省的比價(jià)效應(yīng)，有利于提高藥企的盈利能力。同時(shí)，即將出臺(tái)的新版基藥目錄的擴(kuò)容將帶動(dòng)基層市場(chǎng)的持續(xù)增長(zhǎng)，主要是由于基本藥物報(bào)銷比例明顯高于非基本藥物，基藥品種的增加無疑將會(huì)加大政府醫(yī)藥衛(wèi)生投入比例。因此，預(yù)計(jì)2013年醫(yī)藥制造業(yè)利潤增速將繼續(xù)回升。
從長(zhǎng)遠(yuǎn)來看，國家工信部發(fā)布的《醫(yī)藥工業(yè)“十二五”發(fā)展規(guī)劃》明確提出發(fā)展目標(biāo)為形成5個(gè)以上年銷售收入達(dá)到500億元企業(yè)，100個(gè)100億元企業(yè)，*位企業(yè)銷售收入占行業(yè)50%的目標(biāo)。在上述政策鼓勵(lì)及行業(yè)競(jìng)爭(zhēng)背景下，未來行業(yè)集中度將進(jìn)一步提高，凸顯企業(yè)規(guī)模的重要性，企業(yè)核心競(jìng)爭(zhēng)力的打造將決定企業(yè)未來的發(fā)展。
2012年，三年新醫(yī)改結(jié)束，醫(yī)藥行業(yè)進(jìn)入后醫(yī)改時(shí)代。回首三年新醫(yī)改，政府不斷加大對(duì)醫(yī)療領(lǐng)域的投入，中國醫(yī)藥市場(chǎng)整體擴(kuò)容，中國醫(yī)藥產(chǎn)業(yè)經(jīng)歷*的發(fā)展機(jī)遇。
醫(yī)藥產(chǎn)業(yè)是國民經(jīng)濟(jì)的重要組成部分，與人民群眾的生命健康和生活質(zhì)量等切身利益密切相關(guān)，是全社會(huì)關(guān)注的熱點(diǎn)，同時(shí)也是構(gòu)建社會(huì)主義和諧社會(huì)的重要內(nèi)容。改革開放以來，中國醫(yī)藥行業(yè)一直保持較快的增長(zhǎng)速度，1978-2011年，醫(yī)藥工業(yè)規(guī)模年均遞增均處于15%以上，規(guī)模不斷擴(kuò)大，經(jīng)濟(jì)運(yùn)行質(zhì)量與效益不斷提高。

日本富士 

我司還提供其它進(jìn)口或國產(chǎn)試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團(tuán)菌、食品安全、化妝品檢測(cè)、藥物濫用檢測(cè)等試劑盒以及日本生研細(xì)菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產(chǎn)品。

想了解更多的產(chǎn)品及服務(wù)請(qǐng)掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司
【市場(chǎng)部】    楊永漢

【】 
【騰訊  】 2042552662
【公司地址】 廣州清華科技園創(chuàng)新基地番禺石樓鎮(zhèn)創(chuàng)啟路63號(hào)二期2幢101-103室

development of
Benefited from the steady promotion of the new medical reform, the added value of the pharmaceutical manufacturing industry maintained a steady growth overall. In the first half of 2012, with the continuous downturn of the domestic economy, the growth rate of the added value of the pharmaceutical manufacturing industry gradually declined. Since entering the third quarter, the "poison capsule" effect has slowed down and the government has promulgated "Guiding Opinions on Health Poverty Alleviation during the 12th Five-Year Plan" and "Guiding Opinions on Carrying Out the Urban and Rural Residents' Disease Insurance" and a series of favorable policies , The market sentiment of the pharmaceutical industry began to pick up. The growth rate of the pharmaceutical manufacturing industry reversed the continuous downward trend since the first half of the year. The growth rate of industrial added value stabilized remarkably and the sales revenue growth of the pharmaceutical industry started to pick up. Among them, the first three quarters, the pharmaceutical manufacturing industry growth rate of 14.6%, up 0.3 percentage points over the first half; pharmaceutical manufacturing sales of 1.206991 trillion yuan, an increase of 19.52%, 0.45 percentage points increase over the first half.
In the first three quarters, China's total exports of pharmaceutical products amounted to 8.958 billion U.S. dollars, up only 1.8% over the same period of last year, a deceleration of 8.4 percentage points from the same period of last year and a decrease of 1.5 percentage points from the first half of the previous year. It is noteworthy that, despite the sharp drop in the monthly import of pharmaceutical products, the overall import of pharmaceutical products still maintains a relatively high level. In the first three quarters, China's total import volume of pharmaceutical products was 10.231 billion U.S. dollars, an increase of 23% over the same period of last year, a deceleration of 18.7 percentage points from the same period of last year and a decrease of 6.9 percentage points from the first half of the previous year. Among them, the monthly import shock from 1.201 billion US dollars in July shocks down to 1.133 billion US dollars in September.
Looking forward to 2013, on the one hand, drug bidding gradually becomes benign. The "ultra-low bidding" model of "base drug bidding" has been gradually improved. The government's "pilot national uniform pricing of essential drugs" can effectively prevent or circumvent the vicious competition of low prices and the parity effect in various provinces, and is conducive to enhancing the profitability of pharmaceutical enterprises . At the same time, the forthcoming expansion of the new version of the list of essential drugs will lead to a sustained growth of the primary market. This is mainly due to the significantly higher proportion of reimbursement of essential drugs than non-essential drugs. The increase in the number of basic drugs will undoubtedly increase the proportion of government medical and health investments. Therefore, it is estimated that the profit growth of pharmaceutical manufacturing industry will continue to rise in 2013.
In the long run, the "Development Plan for the 12th Five-year Plan" of the pharmaceutical industry released by the Ministry of Industry and Information Technology clearly sets the goal of development as forming five or more enterprises with annual sales revenue of 50 billion yuan, 100 enterprises with 100 billion yuan and *00 enterprises Revenue accounted for 50% of the industry's goal. Under the background of policy encouragement and industry competition, the concentration of the industry will further increase in the future, highlighting the importance of the scale of enterprises and building the core competitiveness of enterprises will determine the future development of the enterprises.
In 2012, three years of new medical reform ended, the pharmaceutical industry entered the era of post-reform. Looking back three years of new medical reform, the government has continuously increased investment in the medical field, the overall expansion of the pharmaceutical market in China, the Chinese pharmaceutical industry has experienced unprecedented opportunities for development.
The pharmaceutical industry is an important part of the national economy and is closely related to the vital interests of the people, such as life, health and quality of life. It is a focus of attention of the whole society and an important part of building a harmonious socialist society. Since the reform and opening up, China's pharmaceutical industry has maintained a relatively fast growth rate. From 1978 to 2011, the scale of the pharmaceutical industry increased at an average annual rate of over 15%. The scale of the pharmaceutical industry was constantly expanding, and the quality and efficiency of economic operations were continuously improved.development of
Benefited from the steady promotion of the new medical reform, the added value of the pharmaceutical manufacturing industry maintained a steady growth overall. In the first half of 2012, with the continuous downturn of the domestic economy, the growth rate of the added value of the pharmaceutical manufacturing industry gradually declined. Since entering the third quarter, the "poison capsule" effect has slowed down and the government has promulgated "Guiding Opinions on Health Poverty Alleviation during the 12th Five-Year Plan" and "Guiding Opinions on Carrying Out the Urban and Rural Residents' Disease Insurance" and a series of favorable policies , The market sentiment of the pharmaceutical industry began to pick up. The growth rate of the pharmaceutical manufacturing industry reversed the continuous downward trend since the first half of the year. The growth rate of industrial added value stabilized remarkably and the sales revenue growth of the pharmaceutical industry started to pick up. Among them, the first three quarters, the pharmaceutical manufacturing industry growth rate of 14.6%, up 0.3 percentage points over the first half; pharmaceutical manufacturing sales of 1.206991 trillion yuan, an increase of 19.52%, 0.45 percentage points increase over the first half.
In the first three quarters, China's total exports of pharmaceutical products amounted to 8.958 billion U.S. dollars, up only 1.8% over the same period of last year, a deceleration of 8.4 percentage points from the same period of last year and a decrease of 1.5 percentage points from the first half of the previous year. It is noteworthy that, despite the sharp drop in the monthly import of pharmaceutical products, the overall import of pharmaceutical products still maintains a relatively high level. In the first three quarters, China's total import volume of pharmaceutical products was 10.231 billion U.S. dollars, an increase of 23% over the same period of last year, a deceleration of 18.7 percentage points from the same period of last year and a decrease of 6.9 percentage points from the first half of the previous year. Among them, the monthly import shock from 1.201 billion US dollars in July shocks down to 1.133 billion US dollars in September.
Looking forward to 2013, on the one hand, drug bidding gradually becomes benign. The "ultra-low bidding" model of "base drug bidding" has been gradually improved. The government's "pilot national uniform pricing of essential drugs" can effectively prevent or circumvent the vicious competition of low prices and the parity effect in various provinces, and is conducive to enhancing the profitability of pharmaceutical enterprises . At the same time, the forthcoming expansion of the new version of the list of essential drugs will lead to a sustained growth of the primary market. This is mainly due to the significantly higher proportion of reimbursement of essential drugs than non-essential drugs. The increase in the number of basic drugs will undoubtedly increase the proportion of government medical and health investments. Therefore, it is estimated that the profit growth of pharmaceutical manufacturing industry will continue to rise in 2013.
In the long run, the "Development Plan for the 12th Five-year Plan" of the pharmaceutical industry released by the Ministry of Industry and Information Technology clearly sets the goal of development as forming five or more enterprises with annual sales revenue of 50 billion yuan, 100 enterprises with 100 billion yuan and *00 enterprises Revenue accounted for 50% of the industry's goal. Under the background of policy encouragement and industry competition, the concentration of the industry will further increase in the future, highlighting the importance of the scale of enterprises and building the core competitiveness of enterprises will determine the future development of the enterprises.
In 2012, three years of new medical reform ended, the pharmaceutical industry entered the era of post-reform. Looking back three years of new medical reform, the government has continuously increased investment in the medical field, the overall expansion of the pharmaceutical market in China, the Chinese pharmaceutical industry has experienced unprecedented opportunities for development.
The pharmaceutical industry is an important part of the national economy and is closely related to the vital interests of the people, such as life, health and quality of life. It is a focus of attention of the whole society and an important part of building a harmonious socialist society. Since the reform and opening up, China's pharmaceutical industry has maintained a relatively fast growth rate. From 1978 to 2011, the scale of the pharmaceutical industry increased at an average annual rate of over 15%. The scale of the pharmaceutical industry was constantly expanding, and the quality and efficiency of economic operations were continuously improved.development of
Benefited from the steady promotion of the new medical reform, the added value of the pharmaceutical manufacturing industry maintained a steady growth overall. In the first half of 2012, with the continuous downturn of the domestic economy, the growth rate of the added value of the pharmaceutical manufacturing industry gradually declined. Since entering the third quarter, the "poison capsule" effect has slowed down and the government has promulgated "Guiding Opinions on Health Poverty Alleviation during the 12th Five-Year Plan" and "Guiding Opinions on Carrying Out the Urban and Rural Residents' Disease Insurance" and a series of favorable policies , The market sentiment of the pharmaceutical industry began to pick up. The growth rate of the pharmaceutical manufacturing industry reversed the continuous downward trend since the first half of the year. The growth rate of industrial added value stabilized remarkably and the sales revenue growth of the pharmaceutical industry started to pick up. Among them, the first three quarters, the pharmaceutical manufacturing industry growth rate of 14.6%, up 0.3 percentage points over the first half; pharmaceutical manufacturing sales of 1.206991 trillion yuan, an increase of 19.52%, 0.45 percentage points increase over the first half.
In the first three quarters, China's total exports of pharmaceutical products amounted to 8.958 billion U.S. dollars, up only 1.8% over the same period of last year, a deceleration of 8.4 percentage points from the same period of last year and a decrease of 1.5 percentage points from the first half of the previous year. It is noteworthy that, despite the sharp drop in the monthly import of pharmaceutical products, the overall import of pharmaceutical products still maintains a relatively high level. In the first three quarters, China's total import volume of pharmaceutical products was 10.231 billion U.S. dollars, an increase of 23% over the same period of last year, a deceleration of 18.7 percentage points from the same period of last year and a decrease of 6.9 percentage points from the first half of the previous year. Among them, the monthly import shock from 1.201 billion US dollars in July shocks down to 1.133 billion US dollars in September.
Looking forward to 2013, on the one hand, drug bidding gradually becomes benign. The "ultra-low bidding" model of "base drug bidding" has been gradually improved. The government's "pilot national uniform pricing of essential drugs" can effectively prevent or circumvent the vicious competition of low prices and the parity effect in various provinces, and is conducive to enhancing the profitability of pharmaceutical enterprises . At the same time, the forthcoming expansion of the new version of the list of essential drugs will lead to a sustained growth of the primary market. This is mainly due to the significantly higher proportion of reimbursement of essential drugs than non-essential drugs. The increase in the number of basic drugs will undoubtedly increase the proportion of government medical and health investments. Therefore, it is estimated that the profit growth of pharmaceutical manufacturing industry will continue to rise in 2013.
In the long run, the "Development Plan for the 12th Five-year Plan" of the pharmaceutical industry released by the Ministry of Industry and Information Technology clearly sets the goal of development as forming five or more enterprises with annual sales revenue of 50 billion yuan, 100 enterprises with 100 billion yuan and *00 enterprises Revenue accounted for 50% of the industry's goal. Under the background of policy encouragement and industry competition, the concentration of the industry will further increase in the future, highlighting the importance of the scale of enterprises and building the core competitiveness of enterprises will determine the future development of the enterprises.
In 2012, three years of new medical reform ended, the pharmaceutical industry entered the era of post-reform. Looking back three years of new medical reform, the government has continuously increased investment in the medical field, the overall expansion of the pharmaceutical market in China, the Chinese pharmaceutical industry has experienced unprecedented opportunities for development.
The pharmaceutical industry is an important part of the national economy and is closely related to the vital interests of the people, such as life, health and quality of life. It is a focus of attention of the whole society and an important part of building a harmonious socialist society. Since the reform and opening up, China's pharmaceutical industry has maintained a relatively fast growth rate. From 1978 to 2011, the scale of the pharmaceutical industry increased at an average annual rate of over 15%. The scale of the pharmaceutical industry was constantly expanding, and the quality and efficiency of economic operations were continuously improved.development of
Benefited from the steady promotion of the new medical reform, the added value of the pharmaceutical manufacturing industry maintained a steady growth overall. In the first half of 2012, with the continuous downturn of the domestic economy, the growth rate of the added value of the pharmaceutical manufacturing industry gradually declined. Since entering the third quarter, the "poison capsule" effect has slowed down and the government has promulgated "Guiding Opinions on Health Poverty Alleviation during the 12th Five-Year Plan" and "Guiding Opinions on Carrying Out the Urban and Rural Residents' Disease Insurance" and a series of favorable policies , The market sentiment of the pharmaceutical industry began to pick up. The growth rate of the pharmaceutical manufacturing industry reversed the continuous downward trend since the first half of the year. The growth rate of industrial added value stabilized remarkably and the sales revenue growth of the pharmaceutical industry started to pick up. Among them, the first three quarters, the pharmaceutical manufacturing industry growth rate of 14.6%, up 0.3 percentage points over the first half; pharmaceutical manufacturing sales of 1.206991 trillion yuan, an increase of 19.52%, 0.45 percentage points increase over the first half.
In the first three quarters, China's total exports of pharmaceutical products amounted to 8.958 billion U.S. dollars, up only 1.8% over the same period of last year, a deceleration of 8.4 percentage points from the same period of last year and a decrease of 1.5 percentage points from the first half of the previous year. It is noteworthy that, despite the sharp drop in the monthly import of pharmaceutical products, the overall import of pharmaceutical products still maintains a relatively high level. In the first three quarters, China's total import volume of pharmaceutical products was 10.231 billion U.S. dollars, an increase of 23% over the same period of last year, a deceleration of 18.7 percentage points from the same period of last year and a decrease of 6.9 percentage points from the first half of the previous year. Among them, the monthly import shock from 1.201 billion US dollars in July shocks down to 1.133 billion US dollars in September.
Looking forward to 2013, on the one hand, drug bidding gradually becomes benign. The "ultra-low bidding" model of "base drug bidding" has been gradually improved. The government's "pilot national uniform pricing of essential drugs" can effectively prevent or circumvent the vicious competition of low prices and the parity effect in various provinces, and is conducive to enhancing the profitability of pharmaceutical enterprises . At the same time, the forthcoming expansion of the new version of the list of essential drugs will lead to a sustained growth of the primary market. This is mainly due to the significantly higher proportion of reimbursement of essential drugs than non-essential drugs. The increase in the number of basic drugs will undoubtedly increase the proportion of government medical and health investments. Therefore, it is estimated that the profit growth of pharmaceutical manufacturing industry will continue to rise in 2013.
In the long run, the "Development Plan for the 12th Five-year Plan" of the pharmaceutical industry released by the Ministry of Industry and Information Technology clearly sets the goal of development as forming five or more enterprises with annual sales revenue of 50 billion yuan, 100 enterprises with 100 billion yuan and *00 enterprises Revenue accounted for 50% of the industry's goal. Under the background of policy encouragement and industry competition, the concentration of the industry will further increase in the future, highlighting the importance of the scale of enterprises and building the core competitiveness of enterprises will determine the future development of the enterprises.
In 2012, three years of new medical reform ended, the pharmaceutical industry entered the era of post-reform. Looking back three years of new medical reform, the government has continuously increased investment in the medical field, the overall expansion of the pharmaceutical market in China, the Chinese pharmaceutical industry has experienced unprecedented opportunities for development.
The pharmaceutical industry is an important part of the national economy and is closely related to the vital interests of the people, such as life, health and quality of life. It is a focus of attention of the whole society and an important part of building a harmonious socialist society. Since the reform and opening up, China's pharmaceutical industry has maintained a relatively fast growth rate. From 1978 to 2011, the scale of the pharmaceutical industry increased at an average annual rate of over 15%. The scale of the pharmaceutical industry was constantly expanding, and the quality and efficiency of economic operations were continuously improved.